Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

ClinicalUrologyKidney Stone DiseaseTrial Update

Study on Dietary Oxalate's Impact on Kidney Stone Disease and Immunity

This study could reshape dietary recommendations for kidney stone disease, influencing clinical practices and product development in urology. Understanding the relationship between dietary oxalate and immune response may lead to innovative prevention strategies.

Published: June 29, 2026
Updated: June 29, 2026
Author: Humanexa Intelligence
Therapeutic area: Urology / Kidney Stone Disease
Asset: Study
Indication: kidney stone disease treatments
Trial SummaryCLN

Phase III

kidney stone disease treatments

Status

Active

Signal Score

6.8

Signal assessment

Signal strength

moderate

Confidence level

moderate

Signalmoderate
Confidencemoderate

Strategic implication

This study could reshape dietary recommendations for kidney stone disease, influencing clinical practices and product development in urology. Understanding the relationship between dietary oxalate and immune response may lead to innovative prevention strategies.

Why it matters

This study could reshape dietary recommendations for kidney stone disease, influencing clinical practices and product development in urology. Understanding the relationship between dietary oxalate and immune response may lead to innovative prevention strategies.

What changed

Trial Update

Analysis

A study is underway to assess the effects of dietary oxalate on urinary crystals and immune response in healthy individuals.

This study could reshape dietary recommendations for kidney stone disease, influencing clinical practices and product development in urology. Understanding the relationship between dietary oxalate and immune response may lead to innovative prevention strategies.

Monitor study results and any subsequent publications for implications on dietary recommendations in kidney stone management.

Related companies & assets

Assets

  • Study →

Sources & Humanexa intelligence

Source links

  • Study on Dietary Oxalate's Impact on Kidney Stone Disease and Immunity ↗

Related Humanexa pages

  • Study on Dietary Oxalate's Impact on Kidney Stone Disease and Immunity →

Related signals

Trial SummaryCLN

Phase III

Oncology / NSCLC

Status

Active

Signal Score

8.2

Clinicalhigh signal

Novel tumor inflammation score predicts outcomes in NSCLC patients treated with pembrolizumab and gemcitabine

A novel tumor inflammation score based on Treg/T cell relationships predicts treatment outcomes better than traditional biomarkers in NSCLC.

July 5, 2026Read signal →
Trial SummaryCLN

Phase III

hepatocellular carcinoma (HCC)

Status

Active

Sponsor

oncology therapeutics

Signal Score

8.2

Clinicalhigh signal

CENPI identified as a promoter of hepatocellular carcinoma progression via PI3K/AKT/mTOR pathway

CENPI is linked to hepatocellular carcinoma progression through activation of the PI3K/AKT/mTOR-CDK2 cascade.

July 5, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.